Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.

Our Experts


University of Pittsburgh Schools of the Health Sciences

UPMC Media Relations

​UPCI Researchers Participate In Multicenter Trial Of Herceptin

PITTSBURGH, June 16, 1998 — The University of Pittsburgh Cancer Institute (UPCI) is participating in a multicenter, open-label study of Herceptin, an investigational drug used to fight breast cancer cells with an excess of HER2 receptors. About 30 percent of metastatic breast cancers are characterized by an excess of the HER2 receptor, which triggers a more aggressive growth of the cancer cells than cancers without HER2.

"The primary objective of this research study is to provide access to Herceptin to patients with an excess of HER2 metastatic breast cancer who have progressive disease and who already have undergone two chemotherapy regimens. The study also characterizes the safety of Herceptin alone or in combination with chemotherapy or hormonal treatment," said Adam Brufsky, M.D., principal investigator and assistant professor of medicine.

This spring, at the meeting of the American Society of Clinical Oncology, researchers reported that Herceptin may prove beneficial if given to women early in the course of disease, and has virtually no side effects beyond chills and transient fever, compared to those typical of chemotherapy, which include hair loss, vomiting and nausea.

Herceptin, a monoclonal antibody, is just one of a group of drugs designed to attack specific cancer cells. Herceptin targets cancer cells that produce HER2 or HER2/neu by binding to the HER2 receptor and is thought to block the receptor site -- preventing tumor growth.

Results of using Herceptin have shown that, in some patients, tumors may grow more slowly than they would without treatment with Herceptin, and in some cases, the tumors decrease in size.

Breast cancer is the most common malignancy among women, with one in nine experiencing a chance of developing breast cancer during their lives. In the United States alone, there are approximately 185,000 new cases of breast cancer each year, and despite advances in early detection and surgical and adjuvant (designed to reduce the risk of breast cancer recurrence) therapy, nearly 50,000 women will develop metastatic disease each year.

For additional information about this study, call UPCI’s Cancer Information and Referral Service at 1-800-237-4PCI (4724). For more information, please visit the UPMC Cancer Centers website.


UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |